Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 1;6(1):71-7.
eCollection 2013.

Serum miR-200c and clinical outcome of patients with advanced esophageal squamous cancer receiving platinum-based chemotherapy

Hong Yu  1 , Bensong Duan  2 , Lin Jiang  3 , Mei Lin  4 , Haihui Sheng  5 , Junxing Huang  4 , Hengjun Gao  6
Affiliations

Serum miR-200c and clinical outcome of patients with advanced esophageal squamous cancer receiving platinum-based chemotherapy

Hong Yu et al. Am J Transl Res. .

Abstract

MicroRNA-200c (miR-200c) influences sensitivity to chemotherapy and radiotherapy in vitro. This study was designed to investigate the prognostic potential of serum miR-200c in patients with advanced esophageal squamous cancer (ESCC). The serum levels of miR-200c was assayed by quantitative RT-PCR in 157 healthy subjects and 157 patients with advanced ESCC who were treated with platinum-based chemotherapy. The serum levels of miR-200c in advanced ESCC patients was significantly increased compared with those in controls (P < 0.001). Serum miR-200c expression was significantly associated with TNM stage (P = 0.037) and treatment response (P = 0.021). Patients with high expression of serum miR-200c had a higher risk for death than those with low expression of serum miR-200c (adjusted hazard ratios = 1.665, 95% confidence intervals: 1.135-2.443, P = 0.009). In conclusion, serum miR-200c may serve as predictor of survival for advanced ESCC and provide information for personalized therapy in advanced ESCC.

Keywords: Esophageal squamous cancer; chemotherapy; miR-200c; microRNA; platinum.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The serum levels of miR-200c in advanced ESCC patients and healthy controls. A: Comparison of miR-200c expression in 157 ESCC patients and 157 healthy controls. B: Comparison of miR-200c expression levels between TNM stage III and TNM stage IV.
Figure 2
Figure 2
Kaplan–Meier curves of overall survival rates of advanced ESCC patients treated with platinum-based chemotherapy according to miR-200c expression.
See this image and copyright information in PMC

References

    1. Enzinger PC, Mayer RJ. Medical progress - Esophageal cancer. N Engl J Med. 2003;349:2241–2252. - PubMed
    1. Zhang T, Wang Q, Zhao D, Cui Y, Cao B, Guo L, Lu SH. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci (Lond) 2011;121:437–447. - PubMed
    1. Hiyama T, Yoshihara M, Tanaka S, Chayama K. Genetic polymorphisms and esophageal cancer risk. Int J Cancer. 2007;121:1643–1658. - PubMed
    1. Barber TW, Duong CP, Leong T, Bressel M, Drummond EG, Hicks RJ. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med. 2012;53:864–871. - PubMed
    1. Tachimori Y, Kanamori N, Uemura N, Hokamura N, Igaki H, Kato H. Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2009;137:49–54. - PubMed

LinkOut - more resources